Everest Medicines Limited (1952.HK)
HKD 50.8
(3.15%)
HKD 50.8
(3.15%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 18.94 Million CNY | 62.79% |
| 2022 | 11.63 Million CNY | 2503.36% |
| 2021 | 447 Thousand CNY | 0.0% |
| 2020 | - CNY | 0.0% |
| 2019 | - CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q3 | 18.94 Million CNY | 72.41% |
| 2023 FY | 18.94 Million CNY | 62.79% |
| 2023 Q4 | 18.94 Million CNY | 0.0% |
| 2023 Q2 | 10.98 Million CNY | 0.0% |
| 2023 Q1 | 10.98 Million CNY | -5.58% |
| 2022 Q4 | 11.63 Million CNY | 0.0% |
| 2022 Q3 | 11.63 Million CNY | 518.99% |
| 2022 Q2 | 1.88 Million CNY | 0.0% |
| 2022 Q1 | 1.88 Million CNY | 320.58% |
| 2022 FY | 11.63 Million CNY | 2503.36% |
| 2021 Q3 | 447 Thousand CNY | 0.0% |
| 2021 Q2 | - CNY | 0.0% |
| 2021 Q1 | - CNY | 0.0% |
| 2021 FY | 447 Thousand CNY | 0.0% |
| 2021 Q4 | 447 Thousand CNY | 0.0% |
| 2020 Q4 | - CNY | 0.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 Q3 | - CNY | 0.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2020 FY | - CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 36.39 Million HKD | 47.945% |
| CK Life Sciences Int'l., (Holdings) Inc. | 1.2 Billion HKD | 98.427% |